254 Results
Biodesix Study Shows Proprietary Device Collects, Separates, and Transports Blood at Ambient Temperature. Findings Suggest Blood Collection Device Simplifies Specimen Collection and Transport While Maintaining Accuracy of Diagnostic Test Results
Biodesix, Inc., a leading diagnostic company in lung cancer, today announced the realignment of their commercial executive team. Kieran O’Kane will be promoted to Chief Commercial Officer (CCO) and Bobbi Coffin, current Chief Marketing Officer, will become the Chief Growth Officer (CGO), effective immediately.
Biodesix, Inc. a leader in lung cancer diagnostics, is extending its blood-based testing portfolio with the release of the Nodify CDT™ test, designed to help physicians identify patients with lung nodules at high risk of lung cancer.
Biodesix, Inc. and Streck, Inc. today announced a Regulatory Cooperation Agreement that will further enable both companies in their pursuit of FDA approval for diagnostic testing services and specimen collection products.
Major League Lacrosse (MLL) today announced a partnership with Biodesix, Inc., whereby Biodesix will be the exclusive provider of COVID-19 testing for the upcoming 2020 MLL season.
Biodesix, Inc. announced initiation of the next phase of their biomarker development program with Merck KGaA, Darmstadt, Germany and Pfizer Inc.
Biodesix, Inc., a leading diagnostic company in lung disease, today announced that it began SARS-CoV-2 Droplet Digital PCR (ddPCR) testing for the virus that causes COVID-19 and will immediately submit for Emergency Use Authorization from the Food and Drug Administration.
AVEO Oncology and Biodesix, Inc. today announced the presentation of results from an investigator-sponsored Phase 1b trial of ficlatuzumab. Learn More!
Data presented at the American College of Chest Physicians (CHEST) annual meeting, demonstrate the value of the Nodify Lung™ testing strategy and confirm previously reported performance of the Nodify XL2® and Nodify CDT™ tests.
Addario Lung Cancer Medical Institute (ALCMI) and Biodesix, Inc. today announced they will begin an observational study to prospectively evaluate the clinical utility of biomarkers.
Biodesix, Inc. (Nasdaq: BDSX) a leading data-driven diagnostic solutions company with a focus in lung disease, today announced publication of an analysis of the company’s Nodify XL2® lung nodule test.
In the retrospective study, mass spectrometry-based proteomic analysis was performed on pretreatment sera derived from advanced NSCLC patients who were treated with nivolumab as part of routine clinical care.
Biodesix has launched the Biodesix WorkSafe™ Program, a customized return to work service for employers. Learn more about the testing program.
Biodesix, Inc. a leading data-driven diagnostic solutions company with a focus in lung disease, today announced financial and operating results for the third quarter ended September 30, 2020 and provided a corporate update.
Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company, is proud to announce the launch and active recruitment of a firstin-class biomarker study aligned with the recommendations from the official 2018 American Thoracic Society (ATS) policy statement on the early detection of lung cancer.
Biodesix, Inc. today announced plans to provide COVID-19 ddPCR diagnostic testing for Colorado State University (CSU) as students return to campus for the fall term, which begins August 24.
Biodesix, Inc. (Nasdaq: BDSX) (“Biodesix”) today announced the pricing of its initial public offering of 4,000,000 shares of its common stock at a public offering price of $18.00 per share.
The Big Ten Conference has entered into strategic partnerships with Biodesix, Inc., a leading diagnostic company with a focus on lung disease, and Quidel Corporation, the manufacturer of the FDA-authorized SOFIA 2 SARS rapid antigen test.
Biodesix today announced the appointment of Jean Franchi and Hany Massarany to the company’s board of directors. Learn more!
The data from these abstracts will be presented as e-posters at the virtual annual meetings of the American Thoracic Society (ATS), American Society of Clinical Oncology (ASCO), and American Association for Cancer Research (AACR).
The Biodesix SARS-CoV-2 ddPCR™ Test detects COVID-19 with greater sensitivity than other available tests, and is now accessible by appointment at drive-up locations in Boulder and Erie.
Biodesix, Inc., a leading diagnostic company in lung disease, today announced that it has collaborated with Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) to launch a blood-based immunoassay-based test that identifies antibodies to SARS-CoV-2, the virus that causes COVID-19.
Biodesix, Inc., a leading diagnostic company in lung disease, today announced a partnership with Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) to bring a COVID-19 Droplet Digital PCR (ddPCR) test to the FDA for an Emergency Use Authorization (EUA) approval to support the escalating need for testing in the U.S.